Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Depression Drugs Market (Drug Class-Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitor, Selective Serotonin Reuptake Inhibitor;Distribution Channel-Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2018-2026

Published by Transparency Market Research Product code 651156
Published Content info 288 Pages
Delivery time: 1-2 business days
Price
Back to Top
Depression Drugs Market (Drug Class-Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitor, Selective Serotonin Reuptake Inhibitor;Distribution Channel-Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2018-2026
Published: May 21, 2018 Content info: 288 Pages
Description

Title:
Depression Drugs Market ( Drug Class - Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitor, Selective Serotonin Reuptake Inhibitor, Central Nervous System (CNS) Stimulant; Disease Type - Major Depressive Disorder, Schizophrenia and Bipolar I Disorder, Selective Serotonin Reuptake Inhibitor Induced; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Depression Drugs Market - Overview:

This report analyzes the global depression drugs market in terms of its current and future scenario. Increase in prevalence of major depression disorders, rise in government initiatives in creating awareness about depression drugs, and growth in geriatric population across the world are expected to drive the depression drugs market during the forecast period.

The report on the global depression drugs market comprises an elaborate executive summary, including a market snapshot that provides information on various segments. It also provides information and data analysis of the global market with respect to its segments based on drug class, disease type, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section. Additionally, the section comprises product pipeline analysis to help understand the scope of the market. The section also provides market share analysis in terms of segments, geography and key players, thus presenting a thorough analysis of the overall competitive scenario in the global depression drugs market.

The global depression drugs market has been classified on the basis of drug class, disease type, distribution channel, and region. Based on drug class, the market has been categorized into atypical antipsychotics, serotonin-norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, central nervous system (CNS) stimulant, and others. In terms of disease type, the market has been classified into major depressive disorder, schizophrenia and bipolar I disorder, selective serotonin reuptake inhibitor induced, and others. Based on distribution channel, the market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Geographically, the global depression drugs market has been categorized into five major regions and key countries in those regions: North America (U.S. and Canada), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, Israel, GCC, and Rest of Middle East & Africa).

The report also profiles major players operating in the global depression drugs market based on various attributes, such as, company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Pfizer Inc., AstraZeneca, Allergan USA, Inc., Novartis AG, GlaxoSmithKline, and Takeda Pharmaceutical Company Ltd.

The global depression drugs market has been segmented as below:

Global Depression Drugs Market, by Drug Class

  • Atypical antipsychotics
  • Serotonin-norepinephrine reuptake inhibitors
  • Selective serotonin reuptake inhibitors
  • CNS stimulants
  • Others (Benzodiazepines and miscellaneous antidepressants)

Global Depression Drugs Market, by Disease Type

  • Major depressive disorders
  • Schizophrenia and bipolar I disorder (manic depression)
  • SSRI induced
  • Others (attention deficit hyperactivity disorder and anxiety disorders)

Global Depression Drugs Market, by Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Global Depression Drugs Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa
Table of Contents

Table of Contents

1. Preface

  • 1.1. Market Segmentation
  • 1.2. Key Research Objectives
  • 1.3. Research Highlights

2. Assumptions and Acronyms Used

3. Research Approach & Methodology

  • 3.1. Research Methodology overview
  • 3.2. Project Initiation
  • 3.3. Secondary Research Methodology
  • 3.4. Primary Research Methodology
  • 3.5. Analysis Research Methodology
  • 3.6. Final Report & Conclusions Research Methodology

4. Executive Summary: Global Depression Drugs Market

5. Market Overview

  • 5.1. Overview
  • 5.2. Key Industry Events and Developments
  • 5.3. Global Depression Drugs Market Forecast and Analysis
  • 5.4. Global Depression Drugs Market Outlook

6. Market Dynamics

  • 6.1. Drivers and Restraints Snapshot Analysis
  • 6.2. Drivers
  • 6.3. Restraints
  • 6.4. Opportunities
  • 6.5. Key Trends
  • 6.6. Pipeline Analysis
  • 6.7. Depression Treatment Market Value Chain Analysis

7. Global Depression Drugs Market, by Drug Class

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Depression Drugs Market, by Drug Class
    • 7.3.1. Atypical antipsychotics
    • 7.3.2. Serotonin-norepinephrine reuptake inhibitors
    • 7.3.3. Selective serotonin reuptake inhibitors
    • 7.3.4. CNS stimulants
    • 7.3.4. Others (Benzodiazepines and miscellaneous antidepressants)
  • 7.4. Global Depression Drugs Market Share Analysis, by Drug Class
  • 7.5. Global Depression Drugs Market Forecast, by Drug Class
  • 7.6. Global Depression Drugs Market Analysis, by Drug Class

8. Global Depression Drugs Market, by Disease Type

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Global Depression Drugs Market, by Disease Type
    • 8.3.1. Major Depressive Disorder
    • 8.3.2. Schizophrenia and bipolar I disorder (manic depression)
    • 8.3.3. SSRI induced
    • 8.3.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
  • 8.4. Global Depression Drugs Market Value Share Analysis, by Disease Type
  • 8.5. Global Depression Drugs Market Forecast, by Disease Type
  • 8.6. Global Depression Drugs Market Analysis, by Disease Type

9. Global Depression Drugs Market, by Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Global Depression Drugs Market, by Distribution Channel
    • 9.3.1. Hospital pharmacies
    • 9.3.2. Retail pharmacies
    • 9.3.3. Online pharmacies
  • 9.4. Global Depression Drugs Market Share Analysis, by Distribution Channel
  • 9.5. Global Depression Drugs Market Forecast, by Distribution Channel
  • 9.6. Global Depression Drugs Market Analysis, by Distribution Channel

10. Global Depression Drugs Market, by Region

  • 10.1. Global Depression Drugs Market Snapshot, by Country/Sub-region
  • 10.2. Global Depression Drugs Market Analysis, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Global Depression Drugs Market Forecast, by Region

11. North America Depression Drugs Market Analysis

  • 11.1. Policies and Regulations: U.S.
  • 11.2. Key Findings
  • 11.3. North America Depression Drugs Market Overview
  • 11.4. North America Depression Drugs Market Value Share Analysis, by Drug Class
  • 11.5. North America Depression Drugs Market Forecast, by Drug Class
    • 11.5.1. Atypical antipsychotics
    • 11.5.2. Serotonin-norepinephrine reuptake inhibitors
    • 11.5.3. Selective serotonin reuptake inhibitors
    • 11.5.4. CNS stimulants
    • 11.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
  • 11.6. North America Depression Drugs Market Value Share Analysis, by Disease Type
  • 11.7. North America Depression Drugs Market Forecast, by Disease Type
    • 11.7.1. Major depressive disorder
    • 11.7.2. Schizophrenia and bipolar I disorder (manic depression)
    • 11.7.3. Selective serotonin reuptake inhibitors induced
    • 11.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
  • 11.8. North America Depression Drugs Market Value Share Analysis, by Distribution Channel
  • 11.9. North America Depression Drugs Market Forecast, by Distribution Channel
    • 11.9.1. Hospital pharmacies
    • 11.9.2. Retail pharmacies
    • 11.9.3. Online pharmacies
  • 11.10. North America Depression Drugs Market Value Share Analysis, by Country
  • 11.11. North America Depression Drugs Market Forecast, by Country
    • 11.11.1. U.S.
    • 11.11.2. Canada
  • 11.12. Market Trends North America

12. Europe Depression Drugs Market Analysis

  • 12.1. Policies and Regulations: Europe
  • 12.2. Key Findings
  • 12.3. Europe Depression Drugs Market Overview
  • 12.4. Europe Depression Drugs Market Value Share Analysis, by Drug Class
  • 12.5. Europe Depression Drugs Market Forecast, by Drug Class
    • 12.5.1. Atypical antipsychotics
    • 12.5.2. Serotonin-norepinephrine reuptake inhibitors
    • 12.5.3. Selective serotonin reuptake inhibitors
    • 12.5.4. CNS stimulants
    • 12.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
  • 12.6. Europe Depression Drugs Market Value Share Analysis, by Disease Type
  • 12.7. Europe Depression Drugs Market Forecast, by Disease Type
    • 12.7.1. Major depressive disorder
    • 12.7.2. Schizophrenia and bipolar I disorder (manic depression)
    • 12.7.3. Selective serotonin reuptake inhibitors induced
    • 12.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
  • 12.8. Europe Depression Drugs Market Value Share Analysis, by Distribution Channel
  • 12.9. Europe Depression Drugs Market Forecast, by Distribution Channel
    • 12.9.1. Hospital pharmacies
    • 12.9.2. Retail pharmacies
    • 12.9.3. Online pharmacies
  • 12.10. Europe Depression Drugs Market Value Share Analysis, by Country
  • 12.11. Europe Depression Drugs Market Forecast, by Country
    • 12.11.1. Germany
    • 12.11.2. France
    • 12.11.3. Italy
    • 12.11.4. Spain
    • 12.11.5. U.K.
    • 12.11.6. Rest of Europe
  • 12.12. Market Trends Europe

13. Asia Pacific Depression Drugs Market Analysis

  • 13.1. Policies and Regulations: Asia Pacific
  • 13.2. Key Findings
  • 13.3. Asia Pacific Depression Drugs Market Overview
  • 13.4. Asia Pacific Depression Drugs Market Value Share Analysis, by Drug Class
  • 13.5. Asia Pacific Depression Drugs Market Forecast, by Drug Class
    • 13.5.1. Atypical antipsychotics
    • 13.5.2. Serotonin-norepinephrine reuptake inhibitors
    • 13.5.3. Selective serotonin reuptake inhibitors
    • 13.5.4. CNS stimulants
    • 13.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
  • 13.6. Asia Pacific depression drugs Market Value Share Analysis, by Disease Type
  • 13.7. Asia Pacific Depression Drugs Market Forecast, by Disease Type
    • 13.7.1. Major depressive disorder
    • 13.7.2. Schizophrenia and bipolar I disorder (manic depression)
    • 13.7.3. Selective serotonin reuptake inhibitors induced
    • 13.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
  • 13.8. Asia Pacific Depression Drugs Market Value Share Analysis, by Distribution Channel
  • 13.9. Asia Pacific Depression Drugs Market Forecast, by Distribution Channel
    • 13.9.1. Hospital pharmacies
    • 13.9.2. Retail pharmacies
    • 13.9.3. Online pharmacies
  • 13.10. Asia Pacific Depression Drugs Market Value Share Analysis, by Country
  • 13.11. Asia Pacific Depression Drugs Market Forecast, by Country
    • 13.11.1. China
    • 13.11.2. Japan
    • 13.11.3. India
    • 13.11.4. Australia & New Zealand
    • 13.11.5. Rest of Asia Pacific
  • 13.12. Market Trends Asia Pacific

14. Latin America Depression Drugs Market Analysis

  • 14.1. Policies and Regulations: Latin America
  • 14.2. Key Findings
  • 14.3. Latin America Depression Drugs Market Overview
  • 14.4. Latin America Depression Drugs Market Value Share Analysis, by Drug Class
  • 14.5. Latin America Depression Drugs Market Forecast, by Drug Class
    • 14.5.1. Atypical antipsychotics
    • 14.5.2. Serotonin-norepinephrine reuptake inhibitors
    • 14.5.3. Selective serotonin reuptake inhibitors
    • 14.5.4. CNS stimulants
    • 14.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
  • 14.6. Latin America depression drugs Market Value Share Analysis, by Disease Type
  • 14.7. Latin America Depression Drugs Market Forecast, by Disease Type
    • 14.7.1. Major depressive disorder
    • 14.7.2. Schizophrenia and bipolar I disorder (manic depression)
    • 14.7.3. Selective serotonin reuptake inhibitors induced
    • 14.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
  • 14.8. Latin America Depression Drugs Market Value Share Analysis, by Distribution Channel
  • 14.9. Latin America Depression Drugs Market Forecast, by Distribution Channel
    • 14.9.1. Hospital pharmacies
    • 14.9.2. Retail pharmacies
    • 14.9.3. Online pharmacies
  • 14.10. Latin America Depression Drugs Market Value Share Analysis, by Country
  • 14.11. Latin America Depression Drugs Market Forecast, by Country
    • 14.11.1. Brazil
    • 14.11.2. Mexico
    • 14.11.3. Rest of Latin America
  • 14.12. Market Trends Latin America

15. Middle East & Africa Depression Drugs Market Analysis

  • 15.1. Policies and Regulations: Middle East & Africa
  • 15.2. Key Findings
  • 15.3. Middle East & Africa Depression Drugs Market Overview
  • 15.4. Middle East & Africa Depression Drugs Market Value Share Analysis, by Drug Class
  • 15.5. Middle East & Africa Depression Drugs Market Forecast, by Drug class
    • 15.5.1. Atypical antipsychotics
    • 15.5.2. Serotonin-norepinephrine reuptake inhibitors
    • 15.5.3. Selective serotonin reuptake inhibitors
    • 15.5.4. CNS stimulants
    • 15.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
  • 15.6. Middle East & Africa Depression Drugs Market Value Share Analysis, by Disease Type
  • 15.7. Middle East & Africa Depression Drugs Market Forecast, by Disease Type
    • 15.7.1. Major depressive disorder
    • 15.7.2. Schizophrenia and bipolar I disorder (manic depression)
    • 15.7.3. Selective serotonin reuptake inhibitors induced
    • 15.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
  • 15.8. Middle East & Africa Depression Drugs Market Value Share Analysis, by Distribution Channel
  • 15.9. Middle East & Africa Depression Drugs Market Forecast, by Distribution Channel
    • 15.9.1. Hospital pharmacies
    • 15.9.2. Retail pharmacies
    • 15.9.3. Online pharmacies
  • 15.10. Middle East & Africa Depression Drugs Market Value Share Analysis, by Country
  • 15.11. Middle East & Africa Depression Drugs Market Forecast, by Country
    • 15.11.1. GCC
    • 15.11.2. South Africa
    • 15.11.3. Israel
    • 15.11.4. Rest of Middle East & Africa
  • 15.12. Market Trends Middle East & Africa

16. Competition Landscape

  • 16.1. Competition Matrix
  • 16.2. Depression Drugs Market Share Analysis, by Company
  • 16.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 16.3.1. Otsuka Pharmaceutical Co., Ltd.
      • 16.3.1.1. Company Description
      • 16.3.1.2. Financial Overview
      • 16.3.1.3. Recent Developments
      • 16.3.1.4. Strategic Overview
      • 16.3.1.4. SWOT Analysis
    • 16.3.2. Eli Lilly and Company
      • 16.3.2.1. Company Description
      • 16.3.2.2. Financial Overview
      • 16.3.2.3. Strategic Overview
      • 16.3.2.4. SWOT Analysis
    • 16.3.3. Pfizer, Inc.
      • 16.3.3.1. Company Description
      • 16.3.3.2. Financial Overview
      • 16.3.3.3. Strategic Overview
      • 16.3.3.4. SWOT Analysis
    • 16.3.4. AstraZeneca plc.
      • 16.3.4.1. Company Description
      • 16.3.4.2. Financial Overview
      • 16.3.4.3. SWOT Analysis
    • 16.3.5. Novartis AG
      • 16.3.5.1. Company Description
      • 16.3.5.2. Financial Overview
      • 16.3.5.3. Strategic Overview
      • 16.3.5.4. SWOT Analysis
    • 16.3.6. GlaxoSmithKline plc
      • 16.3.6.1. Company Description
      • 16.3.6.2. Financial Overview
      • 16.3.6.3. Strategic Overview
      • 16.3.6.4. Recent Developments
      • 16.3.6.5. SWOT Analysis
    • 16.3.7. Takeda Pharmaceutical Company Ltd
      • 16.3.7.1. Company Description
      • 16.3.7.2. Financial Overview
      • 16.3.7.3. Strategic Overview
      • 16.3.7.4. SWOT Analysis
    • 16.3.8. Sebela Pharmaceutical Inc.
      • 16.3.8.1. Company Description
      • 16.3.8.2. Financial Overview
      • 16.3.8.3. Strategic Overview
      • 16.3.8.3. SWOT Analysis
    • 16.3.9. Allergan USA, Inc.
      • 16.3.9.1. Company Description
      • 16.3.9.2. Financial Overview
      • 16.3.9.3. Strategic Overview
      • 16.3.9.3. SWOT Analysis
    • 16.3.10. Johnson & Johnson
      • 16.3.10.1. Company Description
      • 16.3.10.2. Financial Overview
      • 16.3.10.3. Strategic Overview
      • 16.3.10.4. SWOT Analysis

List of Tables

  • Table 01: Opportunity Map, by Drug Class, 2017
  • Table 02: Opportunity Map, by Disease Type, 2017
  • Table 03: Opportunity Map, by Distribution Channel, 2017
  • Table 04: Global Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2026
  • Table 05: Global Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 06: Global Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 07: Global Depression Drugs Market (US$ Mn) Forecast, by Region, 2016-2026
  • Table 08: North America Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 09: North America Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 10: North America Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 11: North America Depression Drugs Market Size (US$ Mn) Forecast, by Country, 2016-2026
  • Table 12: U.S. Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 13: U.S. Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 14: U.S. Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 15: Canada Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 16: Canada Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 17: Canada Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 18: Europe Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 19: Europe Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 20: Europe Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 21: Europe Depression Drugs Market Size (US$ Mn) Forecast, by Country, 2016-2026
  • Table 22: Germany Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 23: Germany Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 24: Germany Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 25: France Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 26: France Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 27: France Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 28: Italy Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 29: Italy Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 30: Italy Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 31: Spain Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 32: Spain Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 33: Spain Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 34: U.K. Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 35: U.K. Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 36: U.K. Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 37: Rest of Europe Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 38: Rest of Europe Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 39: Rest of Europe Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 40: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 41: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 42: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 43: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Country, 2016-2026
  • Table 44: China Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 45: China Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 46: China Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 47: Japan Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 48: Japan Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 49: Japan Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 50: India Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 51: India Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 52: India Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 53: Australia & New Zealand Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 54: Australia & New Zealand Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 55: Australia & New Zealand Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 56: Rest of Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 57: Rest of Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 58: Rest of Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 59: Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 60: Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 61: Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 62: Latin America depression drugs Market Size (US$ Mn) Forecast, by Country, 2016-2026
  • Table 63: Brazil Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 64: Brazil Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 65: Brazil Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 66: Mexico Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 67: Mexico Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 68: Mexico Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 69: Rest of Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 70: Rest of Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 71: Rest of Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 72: Middle East & Africa depression drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 73: Middle East & Africa depression drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 74: Middle East & Africa depression drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 75: Middle East & Africa depression drugs Market Size (US$ Mn) Forecast, by Country, 2016-2026
  • Table 76: GCC Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 77: GCC Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 78: GCC Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 79: South Africa Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 80: South Africa Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 81: South Africa Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 82: Israel Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 83: Israel Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 84: Israel Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 85: Rest of Middle East & Africa Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 86: Rest of Middle East & Africa Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2016-2026
  • Table 87: Rest of Middle East & Africa Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026

List of Figures

  • Figure 01: Global Depression Drugs Market Size (US$ Mn), by Drug Class, 2017 (A)
  • Figure 02: Global Depression Drugs Market Revenue (%), 2017 (A)
  • Figure 03: Global Depression Drugs Market Size (US$ Mn) Forecast, 2016-2026
  • Figure 04: Market Value Share, by Drug Class (2017)
  • Figure 05: Market Value Share, by Disease Type (2017)
  • Figure 06: Market Value Share, by Distribution Channel (2017)
  • Figure 07: Market Value Share, by Region (2017)
  • Figure 08: Global Depression Drugs Market Value Share, by Valence, 2017 and 2026
  • Figure 09: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Atypical antipsychotics, 2017-2026
  • Figure 10: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by SNRI, 2017-2026
  • Figure 11: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by SSRI, 2017-2026
  • Figure 12: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CNS stimulants, 2017-2026
  • Figure 13: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017-2026
  • Figure 14: Global Depression Drugs Market Value Share, by Disease Type, 2017 and 2026
  • Figure 15: Global Depression Drugs Market Revenue (US$ Mn), by MDD, 2017-2025
  • Figure 16: Global Depression Drugs Market Revenue (US$ Mn), by Schizophrenia and bipolar I disorder, 2017-2025
  • Figure 17: Global Depression Drugs Market Revenue (US$ Mn), by SSRI induced, 2016-2026
  • Figure 18: Global Depression Drugs Market Revenue (US$ Mn), by Others, 2016-2026
  • Figure 19: Global Depression Drugs Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 20: Global Depression Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital pharmacies, 2016-2026
  • Figure 21: Global Depression Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail pharmacies, 2016-2026
  • Figure 22: Global Depression Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online pharmacies, 2016-2026
  • Figure 23: Global Depression Drugs Market Analysis, by Region, 2017 and 2026
  • Figure 24: North America Depression Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 25: North America Depression Drugs Market Value Share, by Drug Class, 2017 and 2026
  • Figure 26: North America Depression Drugs Market Value Share, by Disease Type, 2017 and 2026
  • Figure 27: North America Depression Drugs Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 28: North America Depression Drugs Market Value Share, by Country, 2017 and 2026
  • Figure 29: Europe Depression Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 30: Europe Depression Drugs Market Value Share, by Drug Class, 2017 and 2026
  • Figure 31: Europe Depression Drugs Market Value Share, by Disease Type, 2017 and 2026
  • Figure 32: Europe Depression Drugs Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 33: Europe Depression Drugs Market Value Share, by Country/Sub Region, 2017 and 2026
  • Figure 34: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 35: Asia Pacific Depression Drugs Market Value Share, by Drug Class, 2017 and 2026
  • Figure 36: Asia Pacific Depression Drugs Market Value Share, by Disease Type, 2017 and 2026
  • Figure 37: Asia Pacific Depression Drugs Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 38: Asia Pacific Depression Drugs Market Value Share, by Country/Sub Region, 2017 and 2026
  • Figure 39: Latin America depression drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 40: Latin America Depression Drugs Market Value Share, by Drug Class, 2017 and 2026
  • Figure 41: Latin America Depression Drugs Market Value Share, by Disease Type, 2017 and 2026
  • Figure 42: Latin America Depression Drugs Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 43: Latin America Depression Drugs Market Value Share, by Country, 2017 and 2026
  • Figure 44: Middle East & Africa Depression Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016-2026
  • Figure 45: Middle East & Africa Depression Drugs Market Value Share, by Drug Class, 2017 and 2026
  • Figure 46: Middle East & Africa Depression Drugs Market Value Share, by Disease Type, 2017 and 2026
  • Figure 47: Middle East & Africa Depression Drugs Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 48: Middle East & Africa Depression Drugs Market Value Share, by Country/Sub Region, 2017 and 2026
  • Figure 49: Depression Drugs Sales Analysis, 2014-2016
  • Figure 50: Depression Drugs Market Share, by Company, 2017
Back to Top